The link between cervical cancer and Human Papillomavirus (HPV) has become clear over the past few decades — today we know that persistent infection with specific types of HPV account for nearly all cases of cervical cancer.
Cervical cancer rarely causes overt symptoms in its early stages — when treatment is most effective — so screening for the types of HPV infection at the greatest risk of progressing to cervical pre-cancer and cancer is imperative.
The cobas® HPV test is clinically validated and FDA-approved to provide individual results for HPV 16 and HPV 18, along with a simultaneous, pooled result for other high-risk genotypes, all in one run, from one patient sample. By providing 3-in-1 results, clinicians are able to better risk stratify patients, and make patient management decisions with confidence.